Press

Here you will find the latest press releases and publications of Cytosorbents.
Please send direct inquiries and interview requests to: media@cytosorb-therapy.com.

Terumo Cardiovascular Group and CytoSorbents Announce CytoSorb Cardiac Surgery Partnership

12.09.2016

Agreement brings innovative anti-inflammatory treatment to cardiac surgery teams in six European countries

ANN ARBOR, MI, and MONMOUTH JUNCTION, NJ, SEPTEMBER 12, 2016 – Terumo Cardiovascular Group, a global leader in medical devices for cardiac and vascular surgery and subsidiary of Japan-based Terumo Corporation (TSE: 4543), and CytoSorbents Corporation (NASDAQ: CTSO), manufacturer of the CytoSorb® extracorporeal blood purification adsorber that reduces excessive levels of inflammatory mediators in critically-ill and cardiac surgery patients, announced today that they have entered into a multi-country strategic partnership to commercialize CytoSorb for cardiac surgery applications.more…

This Blood Filtering System Could Help Lower The Risk of Death From Inflammatory Infections

28.08.2016

Trauma to the body comes in many forms – severe burns, gun shot wounds, liver failure, drug overdose, sepsis – which can be deadly. Treating these types of trauma to the body means people end up in the intensive care unit (ICU).

The overall coast of ICU care in the US has doubled in the past ten years to $108 billion. Sepis, is one of the primary cause of death from infection in ICU.

Dr. Neil Halpern, Chief of the Critical Medicine Service and Medical Director of Respiratory Therapy at Memorial Sloan Kettering, New York, says technology plays a key role in keeping patients with sepsis and other critical illnesses alive in the ICU.more…

view source

CytoSorbents Announces FDA Approval to Commence Initial U.S. Cardiac Surgery Study

February 2nd, 2015

MONMOUTH JUNCTION, N.J., Feb. 2, 2015 /PRNewswire/ — CytoSorbents Corporation (NASDAQ CM: CTSO), a critical care immunotherapy company commercializing its CytoSorb® extracorporeal cytokine adsorber to treat critically-ill and cardiac surgery patients in multiple countries worldwide, announced that the U.S. Food and Drug Administration (FDA) has approved its Investigational Device Exemption (IDE) application to commence a planned U.S. cardiac surgery feasibility study. more…

view source

Innovations in medicine: The stabilizer

spiegel.de, 5.01.2015

from Christian Heinrich

Blood poisoning is the third leading cause of death in Germany. Using a new cylindrical apparatus doctors could potentially save more people. Episode one of our series on medical innovations.

more…

view source

Prince William presents Great Tech award

9.12.2014

Prince William, Duke of Cambridge presents an award to Dr. Phillip Chan, CEO of CytoSorbents Corporation during the Innovation is GREAT Reception at Shutterstock headquarters in the Empire State Building on December 9, 2014 in New York City. The reception was technology themed and the winners of the GREAT Tech Awards were presented with trophies. New York City Mayor Bill De Blasio and British Consul General, New York Danny Lopez also congratulated Dr. Chan and the other winners of the award.

more…

view source

Global threat to humanity

welt.de 13.9.2014

from Erik Klapp

On September 13, doctors all over the world celebrate the World Sepsis Day – and for the first time have hope for a cure: A new medical technology can stop the deadly disease.
more…

view source

New cytokine adsorber in use against SIRS and SEPSIS

Kardiotechnik 2/14

English translation courtesy of Kardiotechnik Verwaltungsgesellschaft mbH

One of the most common complications during and after cardio-surgery operations using heart-lung machines is the SIRS (Systemic Inflammatory Response Syndrome). more…

view source